Business Segments · R&D
Business Segments — R&D
Neurocrine Biosciences Business Segments — R&D increased by 14.7% to $296.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.5%, from $263.20M to $296.20M. Over 3 years (FY 2022 to FY 2025), Business Segments — R&D shows an upward trend with a 29.9% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 5, 2026
Rolls up toR&D
How to read this metric
An increase reflects aggressive investment in the pipeline, which may signal future growth potential but impacts current profitability.
Detailed definition
Captures the ongoing investment in clinical trials, drug discovery, and scientific research necessary to advance the com...
Peer comparison
Standard industry metric; peers in the biotech sector often spend a high percentage of revenue on R&D.
Metric ID:
nbix_segment_reportable_segment_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $115.95M | $115.95M | $115.95M | $115.95M | $141.25M | $141.25M | $141.25M | $141.25M | $159.40M | $191.10M | $195.00M | $185.60M | $263.20M | $244.30M | $250.00M | $258.20M | $296.20M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +21.8% | +0.0% | +0.0% | +0.0% | +12.8% | +19.9% | +2.0% | -4.8% | +41.8% | -7.2% | +2.3% | +3.3% | +14.7% |
| YoY Change | — | — | — | — | +21.8% | +21.8% | +21.8% | +21.8% | +12.8% | +35.3% | +38.1% | +31.4% | +65.1% | +27.8% | +28.2% | +39.1% | +12.5% |
Range$115.95M – $296.20M
CAGR+26.4%
Avg YoY Growth+29.1%
Median YoY Growth+27.8%
Current Streak3 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's business segments — r&d?
- Neurocrine Biosciences (NBIX) reported business segments — r&d of $296.20M in Q1 2026.
- How has Neurocrine Biosciences's business segments — r&d changed year-over-year?
- Neurocrine Biosciences's business segments — r&d increased by 12.5% year-over-year, from $263.20M to $296.20M.
- What is the long-term trend for Neurocrine Biosciences's business segments — r&d?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's business segments — r&d has grown at a 29.9% compound annual growth rate (CAGR), from $463.80M to $1.02B.
- What does business segments — r&d mean?
- The total spending on developing new drugs and improving existing ones.